What is the difference between Cagrilintide and Tirzepatide?

Cagrilintide (Cagrilintide (long-acting amylin analog)) is graded A and is Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress. Tirzepatide (Tirzepatide (Mounjaro / Zepbound)) is graded A+ and is FDA-approved for weight management and type 2 diabetes. They are commonly compared because they share the categories: weight-loss, metabolic.

Which has stronger clinical evidence — Cagrilintide or Tirzepatide?

On our internal evidence scale, Cagrilintide is A and Tirzepatide is A+. A+ indicates large RCTs plus FDA approval; C indicates primarily preclinical or anecdotal evidence.

What is the typical dose of Cagrilintide vs Tirzepatide?

Cagrilintide: Trial range: 0.16–4.5 mg weekly (subcutaneous). Tirzepatide: 2.5–15 mg weekly (subcutaneous injection). Always work with a licensed clinician — peptide dosing should be individualized.

Cagrilintide vs Tirzepatide

Both Cagrilintide and Tirzepatide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Cagrilintide

Evidence A

Cagrilintide (long-acting amylin analog)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

View full Cagrilintide profile →

Tirzepatide

Evidence A+

Tirzepatide (Mounjaro / Zepbound)

A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.

View full Tirzepatide profile →

Side-by-Side

Attribute	Cagrilintide	Tirzepatide
Evidence Grade	A	A+
FDA Status	Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress	FDA-approved for weight management and type 2 diabetes
Typical Dose	Trial range: 0.16–4.5 mg weekly (subcutaneous)	2.5–15 mg weekly (subcutaneous injection)
Clinics Indexed	8	1,850
Categories	weight-loss, metabolic	weight-loss, metabolic

Key reported benefits — Cagrilintide

✓Amylin pathway weight loss
✓Synergy with GLP-1
✓Lower-dose tolerability

Key reported benefits — Tirzepatide

✓Superior weight loss
✓Dual hormone targeting
✓Blood sugar control
✓Reduced cardiovascular risk

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons